Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · December 09, 2021

Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment

JAMA Oncology

 

Additional Info

JAMA Oncology
Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment
JAMA Oncol 2021 Nov 23;[EPub Ahead of Print], Y Rottenberg, A Grinshpun, IZ Ben-Dov, E Oiknine Djian, DG Wolf, L Kadouri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading